Xarelto Lawsuit Plaintiff Draws Questions Surrounding Drug’s 24 Hour, One-Pill Dosage

February 10, 2016 – – BloodThinnerHelp.com reports on an especially remarkable Xarelto lawsuit which was filed in a State Court in Pennsylvania. The suit names Xarelto manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) as the defendant, and is especially notable as it poses a different claim than many of the others. The suit claims that the drug’s recommended one pill per day dose is ineffective for a full 24-hours. Court document details support this claim, as they explain that the plaintiff suffered a stroke only four days after beginning to take Xarelto. Ironically, the man was taking Xarelto in order to prevent the very occurrence of a stroke due to his atrial fibrillation condition.

The one pill per day dosage instructions on Xarelto are unlike dosage suggestions on any other blood thinner. No other blood thinner offers one pill per day, one-size-fits-all dosing. Some argue that this is because this dosing option is insufficient. Whatever the reason, all other blood thinners require at least 2 doses of medication each day.

After suffering from his stroke, the plaintiff moved to file suit against the drug manufacturer on October 8, 2015. He not only states that the drug was not effective for a 24-hour period to prevent his stroke, but he also claims that Xarelto may have even caused the occurrence of his stroke. The anticoagulant has recently been the subject of over 2,800 federally filed lawsuits and over 550 consolidated lawsuits which form a mass tort group in Philadelphia, Pennsylvania. These lawsuits, however, commonly allege that the drug causes an increased risk for dangerous and uncontrollable bleeding episodes.

In 2011, the U.S. Food and Drug Administration (FDA) approved Xarelto for use by patients recovering from knee and hip surgeries or those suffering from deep vein thrombosis. They later expanded this approval to include those with atrial fibrillation, a common heart condition which can put patients at increased risk for stroke. When it launched onto the market as a revolutionary, new-generation blood thinner; it immediately became a popular drug. Today, many who once chose it are questioning that choice.

The 2,800 Xarelto lawsuits which were filed in federal courts across the U.S. have now been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592.

They are being overseen in Louisiana by U.S. District Judge Eldon E. Fallon, and their bellwether trials are expected to be heard in early 2017. As they await further trial preparations, many expect that additional lawsuits will be filed and will join the MDL.

At this time, Attorney Joseph Osborne is working to help ensure that anyone suffering after taking Xarelto will be given the opportunity to explore their legal rights in full. He is currently offering complimentary consultations to affected parties, who may be entitled to substantial compensation.

To request additional information, or to ask questions, please contact Joseph Osborne, Esq. by calling 866-425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008066